FLT3 and acute myeloid leukemia: Due to the high expression of FLT3 in 70 to 100% of AML patients and in a high percentage of ALL cases [3], and approximately 30% of AML patients carried the FLT3 mutation which confers proliferative and survival advantages for leukemia cells, FLT3 may become the potential and ideal target for generating CAR-T cells and possess even more effective cytotoxicity on FLT3-ITD AML.